Inflection Point Acquisition Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paula Sutter
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 34 East 51st Street New York City NY United States of America 10022
- IPO Date
- Nov 12, 2021
- CIK
- 0001844452
- Similar Companies
- Business
- Inflection Point Acquisition Corp. (NASDAQ: IPAX) operates as a special purpose acquisition company focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, primarily targeting middle-market companies in technology, consumer, healthcare and adjacent sectors across North America and Europe; it holds no significant operations prior to completing a business combination and maintains IPO proceeds in trust for deployment upon shareholder approval. Sponsored by Inflection Point Advisors LLC, the company offers access to public markets through its blank-check structure, leveraging a management team with expertise in private equity, investment banking, corporate finance and operational leadership to source and support growth-oriented targets. Formed in November 2020 and headquartered in New York, it serves institutional and retail investors seeking exposure to disruptive growth opportunities via SPAC vehicles. In recent developments, IPAX remains pre-business combination as of late 2025, distinct from affiliated entities such as Inflection Point Acquisition Corp. IV, which entered a definitive agreement in August 2025 to merge with Merlin Labs Inc., a developer of AI-powered autonomous flight technology for defense and aviation, valuing the transaction at approximately $800 million with PIPE commitments upsized to over $200 million by November 2025 in anticipation of a 2026 closing.
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
A1R water and Inflection Point Acquisition Corp. III Announce Upsizing of PIPE Investment to $83.5 Million
Inflection Point Acquisition (NASDAQ:IPAX) Shares Up 3.4% – Here’s Why
Small Cap Stocks Worth Watching – October 28th
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Space SPAC Intuitive Machines Just Went Public: Should You Buy In?
Intuitive Machines (LUNR) Stock Skyrockets 160% Following SPAC Merger
Intuitive Machines stock skyrockets, has tripled in 3 days after SPAC merger completed
Intuitive Machines' post-SPAC war chest depleted by shareholder redemptions
Intuitive Machines Teams with Jacobs to Support NASA JETS II Contract
Space Tech Startup Intuitive Machines Shoots for the Stars With IPO
Intuitive Machines to go public in SPAC deal
Lunar tech company Intuitive Machines to go public via SPAC at near $1 billion valuation
Intuitive Machines to go public as a space exploration company after merger with SPAC Inflection Point Acquisition
Intuitive Machines, a Leading Space Exploration Company, to List on Nasdaq Through Merger with Inflection Point Acquisition Corp.